A clinical stage precision therapeutics company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases.
With an advanced discovery engine which integrates structure-based design and computational algorithms to discover and develop novel, precision therapeutics against both first-in-class and validated but intractable targets in genetically-defined patient populations.
Striving for speed and efficiency by employing a business model that leverages the proven and synergistic capabilities of Jubilant Pharmova Limited's value chain and shared services.
Guided by globally renowned key opinion leaders and scientific advisory board members.